(S)-2-amino-N-(3,5-bis(trifluoromethyl)phenyl)-3-phenylpropanamide | 634187-13-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-N-(3,5-bis(trifluoromethyl)phenyl)-3-phenylpropanamide
• 英文别名: (S)-2-Amino-3-phenyl-N-[3,5-bis(trifluoromethyl)phenyl]propionamide；(2S)-2-amino-N-[3,5-bis(trifluoromethyl)phenyl]-3-phenylpropanamide
• CAS: 634187-13-6
• 化学式: C₁₇H₁₄F₆N₂O
• 分子量: 376.301
• InChiKey: CQYFLDVGACXOPP-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (S)-2-amino-N-(3,5-bis(trifluoromethyl)phenyl)-3-phenylpropanamide 在 4-二甲氨基吡啶 、 三溴化硼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-N-(1-((3,5-bis(trifluoromethyl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)-5-chloro-2-hydroxybenzamide
  参考文献：
  名称：

  Structure–Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection

  摘要：

  The effective treatment of adenovirus (HAdV) infections in immunocompromised patients still poses great challenges. Herein, we reported our continued efforts to optimize a series of salicylamide derivatives as potent inhibitors of HAdV infection. Of these, nine compounds (11, 13, 14, 17, 20, 58, 60, 62, and 70) showed significantly improved anti-HAdV activities with nanomolar to submicromolar IC50 values and high selectivity indexes (SI > 100), indicating better safety windows, compared to those of the lead compound niclosamide. Our mechanistic assays suggest that compounds 13, 62, and 70 exert their activities in the HAdV entry pathway, while compounds 14 and 60 likely target the HAdV DNA replication, and 11, 17, 20, and 58 inhibit later steps after DNA replication. Given the broad anti-viral activity profile of niclosamide, these derivatives may also offer therapeutic potential for other viral infections.

  DOI：

  10.1021/acs.jmedchem.9b01950
• 作为产物：
  描述：

  间二(三氟甲基)苯胺 在 哌啶 、 三氯化磷 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 1.0h， 生成 (S)-2-amino-N-(3,5-bis(trifluoromethyl)phenyl)-3-phenylpropanamide
  参考文献：
  名称：

  具有多种氨基酸连接体的 O-烷基氨基-水杨酰胺衍生物作为强效抗癌剂的构效关系研究

  摘要：

  在我们持续的 SAR 研究工作中，设计、合成了一系列具有各种氨基酸接头的O -烷基氨基栓系水杨酰胺衍生物，并对其作为有效的抗癌剂进行了生物学评估。发现具有不同代表​​性化学结构的五种选定化合物显示出广泛的抗增殖活性，可有效对抗所有测试的 ER 阳性乳腺癌 (BC) 和三阴性乳腺癌 (TNBC) 细胞系，具有低微摩尔 IC 50值。在这些化合物中，化合物9a ( JMX0293 ) 对 MDA-MB-231 细胞系保持良好的效力 (IC 50  = 3.38 ± 0.37 μM)，同时对人类非致瘤性乳腺上皮细胞系 MCF-10A 表现出非常低的毒性 (IC50  > 60 微米）。进一步的机理研究表明，化合物9a可以抑制 STAT3 磷酸化并促进 TNBC MDA-MB-231 细胞凋亡。更重要的是，化合物9a在体内显着抑制 MDA-MB-231 异种移植肿瘤的生长而没有显着毒性，表明其作为

  DOI：

  10.1016/j.ejmech.2022.114229

文献信息

• [EN] SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING<br/>[FR] DÉRIVÉS DE SALICYLAMIDE ET MÉTHODES DE FABRICATION ASSOCIÉES
  申请人：UNIV TEXAS

  公开号：WO2021151104A1

  公开（公告）日：2021-07-29

  Certain embodiments describe antiviral compounds and related methods of using such compounds.

  某些实施例描述了抗病毒化合物及其使用方法。
• Inhibitors against the activation of ap-1 and nfat
  申请人：Muto Susumu

  公开号：US20060100257A1

  公开（公告）日：2006-05-11

  A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物，抑制AP-1的激活，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种，其中X代表连接基，其主链中的原子数为2至5（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂芳基，环Z代表芳烃，除了由式—O-A所表示的基团外，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义，或者是一个杂芳烃，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义。
• Medicament for treatment of diabetes
  申请人：Muto Susumu

  公开号：US20060111409A1

  公开（公告）日：2006-05-25

  A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗糖尿病或糖尿病并发症的药物，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一： 其中，X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳基，除了由公式—O—A所表示的基团外，该芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同，或者可以具有一个或多个取代基的杂环芳基，除了由公式—O—A所表示的基团外，该杂环芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同。
• Antiallergic
  申请人：Muto Susumu

  公开号：US20060122243A1

  公开（公告）日：2006-06-08

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳烃，除了由公式-O-A所表示的基团外，该芳烃还可以具有公式—X-E所表示的基团，其中每个X和E具有上述定义的相同含义，或者该环可以具有一个或多个取代基，除了由公式—O-A所表示的基团外，该环还可以具有公式—X-E所表示的基团，其中A具有上述定义的相同含义，X和E分别具有上述定义的相同含义。
• Immunity-related protein kinase inhibitors
  申请人：Muto Susumu

  公开号：US20060019958A1

  公开（公告）日：2006-01-26

  A medicament having an inhibitory activity against IKK-β and/or MEKK-1 or other protein kinases structurally similar thereto, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物具有对IKK-β和/或MEKK-1或其他结构相似的蛋白激酶的抑制活性，其包括以下通式（I）所表示的化合物或其药学上可接受的盐，以及其水合物和溶剂化物作为活性成分的物质：其中，X表示连接主链中原子数为2至5的连接基（该连接基可以被取代），A表示氢原子或乙酰基，E表示可以被取代的芳基或取代的杂环芳基，环Z表示可以具有一个或多个取代基的芳烃，除了由式-O-A表示的基团外，该芳烃还可以具有式-X-E所表示的基团，其中每个X和E的含义与上述定义相同，或者是可以具有一个或多个取代基的杂环芳烃，除了由式-O-A表示的基团外，该杂环芳烃还可以具有式-X-E所表示的基团，其中每个X和E的含义与上述定义相同。